EUVIMEDEUVIMED entdecken
Crossref

Impact of primary tumor resection in the management of metastatic well‐differentiated neuroendocrine tumors of the small bowel and pancreas

Ashley Russo iD, Timothy DiPeri, Teodora Dumitra, Joshua Tseng, Eric Pletcher, Monica Justo, Courtney Chen, Nicholas Nissen, Farin Amersi, Jun Gong, Andrew Hendifar, Alexandra Gangi

Journal of Neuroendocrinology · 2024

DOI: 10.1111/jne.13399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroendocrinology, 2024. Verfasst von Ashley Russo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Cedars-Sinai Medical Center, California, Los Angeles, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Intestinal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET) often present with advanced disease. Primary tumor resection (PTR) in the setting of unresectable metastatic disease is controversial. Most studies evaluating the impact of PTR on overall survival (OS) have been performed using large population‐based databases, with limited treatment related data. This study aims to determine whether PTR improves OS and progression‐free survival (PFS) in patients with metastatic well‐differentiated GEP‐NET. This is a retrospective single‐institution study of patients with metastatic well‐differentiated GEP‐NET between 1978 and 2021. The primary outcome was OS. The secondary outcome was PFS. Chi‐squared tests and Cox regression were used to perform univariate and multivariate analyses (MVA). OS and PFS were estimated using the Kaplan–Meier method and log‐rank test. Between 1978 and 2021, 505 patients presented with metastatic NET, 151 of whom had well‐differentiated GEP‐NET. PTR was performed in 31 PNET and 77 SBNET patients. PTR was associated with improved median OS for PNET (136 vs. 61 months, p = .003) and SBNET (not reached vs. 79 months, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsIntestinal NeoplasmsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultIntestine, SmallNeoplasm MetastasisStomach NeoplasmsAged, 80 and over

Stichwörter der Autor:innen

gastroenteropancreatic neuroendocrine tumormetastatic neuroendocrine tumorneuroendocrine tumorprimary tumor resection

Autor:innen und Institutionen

  • Department of Surgery, Cedars-Sinai Medical Center, California, Los Angeles, USA.
  • Department of Medicine, Cedars-Sinai Medical Oncology, California, Los Angeles, USA.

ORCID-Profile: Ashley Russo

Zitieren

APA

Russo, A., DiPeri, T., Dumitra, T., Tseng, J., Pletcher, E., Justo, M., Chen, C., Nissen, N., Amersi, F., Gong, J., Hendifar, A., & Gangi, A. (2024). Impact of primary tumor resection in the management of metastatic well‐differentiated neuroendocrine tumors of the small bowel and pancreas. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13399

Vancouver

Russo A, DiPeri T, Dumitra T, Tseng J, Pletcher E, Justo M, et al. Impact of primary tumor resection in the management of metastatic well‐differentiated neuroendocrine tumors of the small bowel and pancreas. Journal of Neuroendocrinology. 2024. doi:10.1111/jne.13399

BibTeX
@article{Russo2024,
  author = {Russo, Ashley and DiPeri, Timothy and Dumitra, Teodora and Tseng, Joshua and Pletcher, Eric and Justo, Monica and Chen, Courtney and Nissen, Nicholas and Amersi, Farin and Gong, Jun and Hendifar, Andrew and Gangi, Alexandra},
  title = {Impact of primary tumor resection in the management of metastatic well‐differentiated neuroendocrine tumors of the small bowel and pancreas},
  journal = {Journal of Neuroendocrinology},
  year = {2024},
  doi = {10.1111/jne.13399}
}
Kostenlos starten →